Edition:
United Kingdom

Amphastar Pharmaceuticals Inc (AMPH.OQ)

AMPH.OQ on NASDAQ Stock Exchange Global Select Market

19.45USD
17 Jan 2018
Change (% chg)

$0.67 (+3.57%)
Prev Close
$18.78
Open
$18.89
Day's High
$19.47
Day's Low
$18.80
Volume
83,941
Avg. Vol
89,197
52-wk High
$19.94
52-wk Low
$12.06

Chart for

About

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.... (more)

Overall

Beta: 1.67
Market Cap(Mil.): $874.95
Shares Outstanding(Mil.): 46.20
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.11 16.44
EPS (TTM): -- -- --
ROI: -- 14.85 10.61
ROE: -- 16.31 14.21

BRIEF-Amphastar Announces Approval For Sodium Nitroprusside Injection, USP

* AMPHASTAR ANNOUNCES APPROVAL FOR SODIUM NITROPRUSSIDE INJECTION, USP

19 Dec 2017

BRIEF-Amphastar Announces Approval For Medroxyprogesterone Acetate Injectable Suspension, USP

* AMPHASTAR ANNOUNCES APPROVAL FOR MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION, USP

29 Nov 2017

BRIEF-Amphastar Pharma reports results for three months ended Sept

* Amphastar Pharmaceuticals reports financial results for the three months ended September 30, 2017

08 Nov 2017

BRIEF-Amphastar Pharmaceuticals receives FDA approval for sodium bicarbonate injection

* Amphastar Pharmaceuticals receives FDA approval for sodium bicarbonate injection

20 Sep 2017

BRIEF-Amphastar Pharmaceuticals reports Q2 earnings per share $0.04

* Amphastar Pharmaceuticals reports financial results for the three months ended june 30, 2017

09 Aug 2017

BRIEF-Amphastar announces jury verdict in litigation against Momenta Pharmaceuticals and Sandoz Inc

* Amphastar announces jury verdict in patent litigation against Momenta Pharmaceuticals Inc and Sandoz Inc

24 Jul 2017

U.S. jury sides with Amphastar over Momenta in drug patent trial

BOSTON A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox.

21 Jul 2017

UPDATE 2-U.S. jury sides with Amphastar over Momenta in drug patent trial

BOSTON, July 21 A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox.

21 Jul 2017

U.S. jury sides with Amphastar over Momenta in drug patent trial

BOSTON, July 21 Amphastar Pharmaceuticals Inc on Friday won a trial in a lawsuit claiming that the drugmaker through its production of a generic version of the blood-thinner Lovenox infringed a patent held by Momenta Pharmaceuticals Inc.

21 Jul 2017

Earnings vs. Estimates